Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy.

However, as the immune improvement caused by ablation is not lasting and is accompanied by tumor constitution; its control effect on distant lesions in the liver may not be significant (unpublished data).

also in 2,774 other papers

Second, although it did not reach a significant difference in most subgroups, the benefit of anti-PD-1 adjuvant therapy showed a positive trend in RFS and could effectively decrease the relapse risk of patients with multiple tumors and tumor size ≤2cm to 79.1% and 89.2%, respectively.

also in 11,005 other papers